<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03390322</url>
  </required_header>
  <id_info>
    <org_study_id>CLD-008</org_study_id>
    <nct_id>NCT03390322</nct_id>
  </id_info>
  <brief_title>Safety and Initial Performance of the DiaGone Device on Type 2 Diabetes Patients</brief_title>
  <official_title>DiaGone™ First in Human (FIH) Study - Safety and Performance of the DiaGone™ Device for the Treatment of Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Digma Medical Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Digma Medical Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, prospective, open label study of the Duodenal Glycemic Control™
      procedure on type 2 diabetes patients sub-optimally controlled, to examine the safety and
      initial performance of the DiaGone™ system.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a multi-center, prospective, open label trial of type 2 diabetes patients
      sub-optimally controlled on at least one oral anti-diabetic medication.

      Subjects who meet all inclusion and exclusion criteria after screening are hospitalized and
      go through the Duodenal Glycemic Control™ treatment.

      Duodenal Glycemic Control™ treatment is conducted by a gastroenterologist, in an endoscopic
      suite, with an off-the-shelf endoscope, using the DiaGone™ system.

      Patients are followed for 6 months for AE and SAE. Patients are followed for 12 months for
      glycemic control parameters.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 28, 2017</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of procedure related SAEs.</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of procedure related SAEs.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change to Fasting Glucose levels</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change to Post Prandial Glucose levels</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change to HbA1c levels</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Duodenal Glycemic Control™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DiaGone™</intervention_name>
    <description>Duodenal Glycemic Control™ using the DiaGone™ system</description>
    <arm_group_label>Duodenal Glycemic Control™</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who are ≥ 18 years and ≤ 75 years of age.

          -  HbA1c at 7.5%-12%

          -  On oral glucose lowering drugs in a stable medication regimen

          -  Fasting plasma glucose level at ≥125mg/dL

          -  BMI 25-40 Kg/m2

        Exclusion Criteria:

          -  Diagnosed Type I diabetes

          -  Serum C peptide &lt;1ng/ml
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chen Botvin Moshe</last_name>
    <phone>+972-(0)54-6703737</phone>
    <email>chenbm@digmamedical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>IKEM</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriela Petranova</last_name>
      <phone>+420 261 365 154</phone>
      <email>Gabriela.Petranova@ikem.cz</email>
    </contact>
    <investigator>
      <last_name>Marek Benes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shaarei Tzedek</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yael Lagemi</last_name>
      <email>yaelagemi@szmc.org.il</email>
    </contact>
    <investigator>
      <last_name>Eran Goldin, Prof, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barcelona Clinical Hospital</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joseph Vidal Cortada</last_name>
      <email>jovidal@clinic.cat</email>
    </contact>
    <investigator>
      <last_name>Joseph Vidal Cortada, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ramón y Cajal Insitute of Health Research</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chen BotvinMoshe</last_name>
      <email>chenbm@digmamedical.com</email>
    </contact>
    <investigator>
      <last_name>Enrique Vazques, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Israel</country>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>https://www.digmamedical.com</url>
  </link>
  <reference>
    <citation>Salinari S, Bertuzzi A, Guidone C, Previti E, Rubino F, Mingrone G. Insulin sensitivity and secretion changes after gastric bypass in normotolerant and diabetic obese subjects. Ann Surg. 2013 Mar;257(3):462-8. doi: 10.1097/SLA.0b013e318269cf5c.</citation>
    <PMID>23388352</PMID>
  </reference>
  <reference>
    <citation>Ferrannini E, Mingrone G. Impact of different bariatric surgical procedures on insulin action and beta-cell function in type 2 diabetes. Diabetes Care. 2009 Mar;32(3):514-20. doi: 10.2337/dc08-1762. Review.</citation>
    <PMID>19246589</PMID>
  </reference>
  <reference>
    <citation>Mingrone G, Castagneto-Gissey L. Mechanisms of early improvement/resolution of type 2 diabetes after bariatric surgery. Diabetes Metab. 2009 Dec;35(6 Pt 2):518-23. doi: 10.1016/S1262-3636(09)73459-7. Review.</citation>
    <PMID>20152737</PMID>
  </reference>
  <reference>
    <citation>de Jonge C, Rensen SS, Verdam FJ, Vincent RP, Bloom SR, Buurman WA, le Roux CW, Schaper NC, Bouvy ND, Greve JW. Endoscopic duodenal-jejunal bypass liner rapidly improves type 2 diabetes. Obes Surg. 2013 Sep;23(9):1354-60. doi: 10.1007/s11695-013-0921-3.</citation>
    <PMID>23526068</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 26, 2017</study_first_submitted>
  <study_first_submitted_qc>January 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 4, 2018</study_first_posted>
  <last_update_submitted>January 3, 2018</last_update_submitted>
  <last_update_submitted_qc>January 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

